Is Injectable Hyaluronic Acid the Future of GSM Relief?

Understanding Genitourinary Syndrome of Menopause
Injectable hyaluronic acid has emerged as an intriguing therapeutic avenue for genitourinary syndrome of menopause. Genitourinary syndrome of menopause (GSM) causes progressive vulvovaginal atrophy and significant physical discomfort. Estrogen deficiency weakens the mucosal barrier and disrupts extracellular matrix integrity. Consequently, patients frequently experience distressing vaginal dryness, burning, and severe dyspareunia. While local hormonal therapy remains the primary standard of care, many women require alternative interventions. For instance, breast cancer survivors often avoid hormonal therapies due to recurrence concerns. Furthermore, patient reluctance often limits long-term adherence to prescription estrogens. Therefore, clinicians actively seek robust non-hormonal treatment alternatives.
Mechanisms and Formulations in Vaginal Restoration
Hyaluronic acid plays an essential physiological role in tissue hydration and viscoelasticity. In healthy vaginal tissue, it binds water molecules and maintains extracellular scaffold structure. Topical creams and gels effectively provide short-term lubrication at the mucosal surface. However, superficial formulations require frequent application and rarely remodel deeper tissues. In contrast, deep injections deliver the molecule directly into the subepithelial layers. Consequently, this targeted delivery may induce sustained structural improvements. Specifically, hybrid cooperative complex hyaluronic acid (HCC-HA) has gained clinical interest. This specialized formulation promotes tissue remodeling while maintaining excellent biocompatibility.
Current Clinical Evidence for Injectable Hyaluronic Acid
Recent clinical studies have evaluated injectable hyaluronic acid in postmenopausal women. Available prospective trials report marked reductions in vaginal dryness and dyspareunia. Moreover, preliminary trials demonstrate notable improvements in tissue turgor and patient comfort. Nevertheless, the existing literature reveals notable limitations. Most clinical trials remain small and examine women with generalized sexual dysfunction. Additionally, research has not demonstrated uniform improvements across all quality-of-life parameters. Fortunately, available data indicate no serious procedural adverse events. However, clinicians still need large randomised trials to confirm long-term safety and durability.
Clinical Implications for Practice
Current international guidelines do not yet recommend routine use of these injectables. Clinicians must distinguish regulatory device approval from rigorous guideline endorsement. Therefore, practitioners should approach these emerging regenerative therapies with evidence-based caution. Thorough patient counseling remains essential before initiating novel office-based procedures. In addition, health-economic considerations must guide clinical decision-making. Future multicenter investigations will ultimately clarify the true position of this therapy in menopausal care.
Frequently Asked Questions
Q1: How does injectable hyaluronic acid differ from topical vaginal moisturizers?
Topical products hydrate the mucosal surface temporarily. Conversely, injections deliver hyaluronic acid into deeper tissues to promote prolonged hydration and structural remodeling.
Q2: Is injectable hyaluronic acid approved as standard therapy for GSM?
Currently, clinical guidelines do not list injectables as routine therapy. While preliminary trials show symptom relief, broader randomized trials must confirm their long-term efficacy.
Q3: Which patients might benefit most from non-hormonal injectable options?
Women with absolute contraindications to estrogens, such as breast cancer survivors, may benefit substantially. Additionally, patients who prefer non-hormonal interventions represent ideal candidates.
References
- Menabrito M et al. Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause. BJOG. 2026 Nov 18. doi: 10.1111/1471-0528.70381. PMID: 43051281.
- Brucker BM et al. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause. 2024;31(9):789-796.
- Cuccu I et al. Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach. Life. 2024;14(11):1452.





